News
The Near-Perfect 7% Income Portfolio: My Blueprint For Financial Freedom
8+ mon, 1+ week ago (474+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S) in Advanced Endometrial Cancer (EC) (2025-08-26)
7+ mon, 3+ week ago (195+ words) Rina-S is advancing through late-stage development supported by a growing portfolio of clinical trials, including the ongoing Phase 1/2 RAINFOL-01 trial, the ongoing Phase 3 RAINFOL-02 trial (NCT06619236) in ovarian cancer, and several planned trials to evaluate Rina-S as a potential treatment option…...
CHAMPION-AF study of the WATCHMAN FLX" Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints (2026-03-28)
2+ week, 4+ day ago (162+ words) Late-breaking findings presented at ACC. 26 and simultaneously published in The New England Journal of Medicine The randomized, controlled trial enrolled 3, 000 patients with NVAF who were suitable for oral anticoagulation therapy across a broad spectrum of stroke and bleeding risk. At…...
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis (2025-12-24)
3+ mon, 3+ week ago (302+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...
Medtronic Brain Sense" Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions (2025-10-09)
6+ mon, 1+ week ago (499+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss (2025-10-17)
5+ mon, 4+ week ago (363+ words) " Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients " " Vision improvements were seen in both pivotal studies, achieving statistical significance in MEERKAT and nominal significance in…...
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study (2025-09-02)
7+ mon, 2+ week ago (196+ words) Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials Enlicitide had a favorable safety profile, with comparable rates of discontinuation between treatment groups About enlicitide and PCSK9 Enlicitide…...
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension (2025-08-30)
7+ mon, 2+ week ago (436+ words) " Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 " In the Phase II KARDIA-3 study, presented today as a late breaker at the European Society of Cardiology Congress 2025, zilebesiran demonstrated…...
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes (2026-02-06)
2+ mon, 1+ week ago (566+ words) Founded in 2004, Seeking Alpha is an industry-leading financial research platform powered by one of the world's largest investing communities. We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to…...
Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript
5+ mon, 5+ day ago (292+ words) Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2: 00 PM EST Sheldon Koenig - President, CEO & Director Le Anne Bloedon - VP & Head of Development Dharmesh Patel Fatima Rodriguez Kyuwon Choi - Goldman…...